Literature DB >> 17109678

Chronic hepatitis B: current epidemiology in the Americas and implications for management.

R G Gish1, A C Gadano.   

Abstract

Hepatitis B virus (HBV) remains a serious health threat in many parts of the world. Although its prevalence is lower in the Americas than in Asia, Africa and the Middle East, it is responsible for significant morbidity and mortality in North, Central and South America. There is a nonuniform pattern of distribution throughout this region, with HBV prevalence related to geographical, social and cultural factors that predispose certain individuals to infection. This report details the incidence, modes of viral transmission of hepatitis B in the Americas and clinical course of disease in different regions of the Americas. Additionally, the implications for management focusing on issues predominant in high-risk populations are presented.

Entities:  

Mesh:

Year:  2006        PMID: 17109678     DOI: 10.1111/j.1365-2893.2006.00787.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  26 in total

1.  Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.

Authors:  Helen Dakin; Morris Sherman; Scott Fung; Carrie Fidler; Anthony Bentley
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

2.  Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study.

Authors:  Steven-Huy Han; K Rajender Reddy; Emmet B Keeffe; Consuelo Soldevila-Pico; Robert Gish; Raymond T Chung; Bulent Degertekin; Anna Lok
Journal:  Clin Transplant       Date:  2010-11-16       Impact factor: 2.863

3.  Hepatitis B prevention and control: Lessons from the East and the West.

Authors:  Monica C Robotin
Journal:  World J Hepatol       Date:  2011-02-27

4.  A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective.

Authors:  Sarah E Post; Neetu Khurana Sodhi; Chia-Hui Peng; Kejia Wan; Henry J Pollack
Journal:  Health Aff (Millwood)       Date:  2011-02       Impact factor: 6.301

5.  A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B.

Authors:  D Eldon Spackman; David L Veenstra
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

6.  "Know Hepatitis B:" A Multilingual Communications Campaign Promoting Testing for Hepatitis B Among Asian Americans and Pacific Islanders.

Authors:  Cynthia Jorgensen; Sherry Chen; C Amanda Carnes; Joan Block; Daniel Chen; Jeffrey Caballero; Kate Moraras; Chari Cohen
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

7.  Economic analysis of hepatitis B screening and treatment.

Authors:  Vincent Lo Re
Journal:  Clin Infect Dis       Date:  2011-05-02       Impact factor: 9.079

8.  Collection of social determinant of health measures in U.S. national surveillance systems for HIV, viral hepatitis, STDs, and TB.

Authors:  Victoria M Beltran; Kathleen McDavid Harrison; H Irene Hall; Hazel D Dean
Journal:  Public Health Rep       Date:  2011 Sep-Oct       Impact factor: 2.792

9.  Hepatitis B (HBV), hepatitis C (HCV) and hepatitis delta (HDV) viruses in the Colombian population--how is the epidemiological situation?

Authors:  Mónica Viviana Alvarado-Mora; María Fernanda Gutierrez Fernandez; Michele Soares Gomes-Gouvêa; Raymundo Soares de Azevedo Neto; Flair José Carrilho; João Renato Rebello Pinho
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

10.  Characterization of hepatitis B virus (HBV) genotypes in patients from Rondônia, Brazil.

Authors:  Alcione O Santos; Mónica V Alvarado-Mora; Lívia Botelho; Deusilene S Vieira; João R Rebello Pinho; Flair J Carrilho; Eduardo R Honda; Juan M Salcedo
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.